In addition to the agreement with Hospira, Human Genome Sciences (HGS) has entered into a marketing services agreement with Eden Biodesign in mid-August 2008, under which Eden Biodesign will assist HGS in identifying other large- scale manufacturing and late-stage process development clients.
Curran Simpson, senior vice president of operations at HGS, said: “The priority focus of HGS continues to be the commercialization of our lead products. Agreements such as this one will produce near-term revenue from available manufacturing capacity. We see potential for $30-60 million in revenue from manufacturing alliances, including this alliance with Hospira, over the next three to four years.”